Clinical Trial Update: PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of post-transplant cyclophosphamide (PTCY) with uhCG/EGF for prophylaxis of graft-versus-host disease, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• post-transplant cyclophosphamide (cyclophosphamide)
• uhCG/EGF

Snippet

Sponsor: Henry Ford Health System | Conditions: Graft Versus Host Disease | Phase 1 | Status: RECRUITING